European Journal of Cancer
Volume 37, Issue 18 , Pages 2457-2463 , December 2001

Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat

  • G Cavaletti

      Affiliations

    • Clinica Neurologica, A.O.S. Gerardo, Monza, Italy
    • Dipartimento di Neuroscienze e Tecnologie Biomediche, Università di Milano “Bicocca”, Monza, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39+233-3495; fax: +39+02+7004-38655
    • ,
  • G Tredici

      Affiliations

    • Dipartimento di Neuroscienze e Tecnologie Biomediche, Università di Milano “Bicocca”, Monza, Italy
    • ,
  • M.G Petruccioli

      Affiliations

    • Dipartimento di Anatomia Umana, Università di Milano, Milano, Italy
    • ,
  • E Dondè

      Affiliations

    • Dipartimento di Neuroscienze e Tecnologie Biomediche, Università di Milano “Bicocca”, Monza, Italy
    • ,
  • P Tredici

      Affiliations

    • Dipartimento di Neuroscienze e Tecnologie Biomediche, Università di Milano “Bicocca”, Monza, Italy
    • ,
  • P Marmiroli

      Affiliations

    • Dipartimento di Neuroscienze e Tecnologie Biomediche, Università di Milano “Bicocca”, Monza, Italy
    • ,
  • C Minoia

      Affiliations

    • Clinica del Lavoro, Fondazione Maugeri, Pavia, Italy
    • ,
  • A Ronchi

      Affiliations

    • Clinica del Lavoro, Fondazione Maugeri, Pavia, Italy
    • ,
  • M Bayssas

      Affiliations

    • Debiopharm S.A., Lausanne, Switzerland
    • ,
  • G Griffon Etienne

      Affiliations

    • Debiopharm S.A., Lausanne, Switzerland

Received 2 April 2001 ,Revised 5 June 2001 ,Accepted 29 August 2001.

References 

  1. Holmes J, Stanko J, Varchenko M, et al.  Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model. Toxicol. Sci. 1998;46:342–351
  2. Mathe G, Kidani Y, Noji M, et al.  Antitumor activity of l-OHP in mice. Cancer Lett. 1985;27:135–143
  3. Tashiro T, Kawada Y, Sakurai Y, Kidani Y. Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)platinum (II) (new experimental data). Biomed. Pharmacother. 1989;43:251–260
  4. de Gramont A, Vignoud J, Tournigand C, et al.  Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur. J. Cancer. 1997;33:214–219
  5. Levi F, Misset JL, Brienza S, et al.  A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer. 1992;69:893–900
  6. Chollet P, Bensmaine MA, Brienza S, et al.  Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann. Oncol. 1996;7:1065–1070
  7. Culy CR, Clemett D, Wiseman LR. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs. 2000;60:895–924
  8. de Gramont A, Figer A, Seymour M, et al.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 2000;18:2938–2947
  9. Giacchetti S, Perpoint B, Zidani R, et al.  Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 2000;18:136–147
  10. Machover D, Diaz-Rubio E, de Gramont A, et al.  Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann. Oncol. 1996;7:95–98
  11. McKeage MJ, Boxall FE, Jones M, Harrap KR. Lack of neurotoxicity of oral bisacetatoamminedichlorocyclohexylamine-platinum(IV) in comparison to cisplatin and tetraplatin in the rat. Cancer Res. 1994;54:629–631
  12. Cavaletti G, Petruccioli MG, Tredici G, et al.  Effects of repeated administration of low doses of cisplatin on the rat nervous system. Int. J. Tissue React. 1991;13:151–157
  13. Cavaletti G, Tredici G, Marmiroli P, et al.  Morphometric study of the sensory neurones and peripheral nerve changes induced by chronic cisplatin (DDP) administration. Acta Neuropathol. 1992;84:364–371
  14. Extra JM, Marty M, Brienza S, Misset JL. Pharmacokinetics and safety profile of oxaliplatin. Semin. Oncol. 1998;25(Suppl. 5):13–22
  15. Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin (a review of preclinical and clinical studies). Ann. Oncol. 1998;9:1053–1071
  16. Gregg RW, Molepo JM, Monpetit VJ, et al.  Cisplatin neurotoxicity (the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity). J. Clin. Oncol. 1992;10:795–803
  17. Tredici G, Tredici S, Fabbrica D, et al.  Experimental cisplatin neuronopathy in rats and the effect of retinoic acid administration. J. Neuroncol. 1998;36:31–40
  18. Cavaletti G, Minoia C, Schieppati M, Tredici G. Protective effects of glutathione on cisplatin neurotoxicity in rats. Int. J. Rad. Oncol. Biol. Phys. 1994;29:771–776
  19. Dondè E, Tredici G, Fagnani E, Cavaletti G. Ototoxicity in experimental cisplatin neuropathy. J Per Nerv Sys 1999, 2, 192–193 (abstr).
  20. Cavaletti G, Fabbrica D, Minoia C, et al.  Carboplatin toxic effects on the peripheral nervous system of the rat. Ann. Oncol. 1998;9:443–447
  21. Cornblath DR, Brown MJ. Influence of malnutrition on developing rat peripheral nerves. Exp. Neurol. 1988;99:403–411

PII: S0959-8049(01)00300-8

doi: 10.1016/S0959-8049(01)00300-8

European Journal of Cancer
Volume 37, Issue 18 , Pages 2457-2463 , December 2001

Article Tools

* Image Usage & Resolution